These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 17530638

  • 1. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
    Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, Stefanadis C, Mavrikakis M.
    Arthritis Rheum; 2007 Jun; 56(6):1985-93. PubMed ID: 17530638
    [Abstract] [Full Text] [Related]

  • 2. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
    Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C.
    Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial.
    Rafnsson A, Böhm F, Settergren M, Gonon A, Brismar K, Pernow J.
    Diabetologia; 2012 Mar; 55(3):600-7. PubMed ID: 22200728
    [Abstract] [Full Text] [Related]

  • 5. Role of endogenous endothelin in endothelial dysfunction in murine model of systemic sclerosis: tight skin mice 1.
    Richard V, Solans V, Favre J, Henry JP, Lallemand F, Thuillez C, Marie I.
    Fundam Clin Pharmacol; 2008 Dec; 22(6):649-55. PubMed ID: 19049669
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Systemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunction.
    Frech T, Walker AE, Barrett-O'Keefe Z, Hopkins PN, Richardson RS, Wray DW, Donato AJ.
    Clin Rheumatol; 2015 May; 34(5):905-13. PubMed ID: 25511849
    [Abstract] [Full Text] [Related]

  • 9. Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production.
    Andersen GN, Mincheva-Nilsson L, Kazzam E, Nyberg G, Klintland N, Petersson AS, Rantapää-Dahlqvist S, Waldenström A, Caidahl K.
    Arthritis Rheum; 2002 May; 46(5):1324-32. PubMed ID: 12115240
    [Abstract] [Full Text] [Related]

  • 10. Impact of endothelin blockade on acute exercise-induced changes in blood flow and endothelial function in type 2 diabetes mellitus.
    Schreuder TH, van Lotringen JH, Hopman MT, Thijssen DH.
    Exp Physiol; 2014 Sep; 99(9):1253-64. PubMed ID: 24928953
    [Abstract] [Full Text] [Related]

  • 11. Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study.
    Cozzi F, Pigatto E, Rizzo M, Favaro M, Zanatta E, Cardarelli S, Riato L, Punzi L.
    Clin Rheumatol; 2013 May; 32(5):679-83. PubMed ID: 23344686
    [Abstract] [Full Text] [Related]

  • 12. The endothelin-1 receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans.
    Böhm F, Settergren M, Gonon AT, Pernow J.
    Clin Sci (Lond); 2005 Apr; 108(4):357-63. PubMed ID: 15610070
    [Abstract] [Full Text] [Related]

  • 13. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C, Praino E, Nivuori M, di Serio F, Lapadula G, Iannone F.
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement.
    Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S.
    Clin Rheumatol; 2005 Apr; 24(2):111-6. PubMed ID: 15349798
    [Abstract] [Full Text] [Related]

  • 18. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M.
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Low circulating level of CD133+KDR+cells in patients with systemic sclerosis.
    Mok MY, Yiu KH, Wong CY, Qiuwaxi J, Lai WH, Wong WS, Tse HF, Lau CS.
    Clin Exp Rheumatol; 2010 Mar; 28(5 Suppl 62):S19-25. PubMed ID: 21050541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.